GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of France: survodutide, and what it actually costs here — 54 comments in the full submission. View in context.
1.3k
c/survodutide·submitted 1 year ago by u/renzo_asante

France: survodutide, and what it actually costs here

Cautionbranch of 5 comments

Confession thread, sort of. I went from 1.0mg to 15mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 14 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have constipation…

Read the full submission and all 54 comments →

This branch

5 comments, started 1 year ago
u/throwaway_wl202640 points·1 year ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/patient_labslip_log11 points·1 year ago

do not generalise from tirzepatide

replysharereportpermalink
u/liver_enzyme_liz19 points·1 year ago

phase 6 data is interesting, phase 18 will be different

replysharereportpermalink
u/fibre_forward22 points·1 year ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/vikram_mbeki15 points·1 year ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.